The Government now has the chance to save countless lives by introducing a targeted screening programme for prostate cancer , the most common cancer among British men.

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

ORNL is a leader both in developing advanced radiotherapies and in providing the radioisotopes needed for those therapies.

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score improvements.

PINELLAS PARK, Fla. — The final minted pennies are getting new homes. More than 230 sets of three were auctioned off online on behalf of the U.S. Mint. Many of them sold for tens of thousands of ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...

Brian Holmes is the first man in the UK and only the fifth in the world to take part in the clinical trial [BBC] A prostate cancer patient hopes a new treatment can help prolong the lives of thousands ...

Samantha Smith of Harrisburg, Pennsylvania, went into the operating room for emergency removal of an ectopic pregnancy. “I’m grateful I didn’t die,” she said, but she was shocked to see ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...